BeiGene
BGNE
#817
Rank
$23.04 B
Marketcap
$205.80
Share price
1.43%
Change (1 day)
-36.73%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: $23.04 Billion

As of January 2022 BeiGene has a market cap of $23.04 Billion. This makes BeiGene the world's 817th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.

Market cap history of BeiGene from 2016 to 2022

Year Market cap Change
2022$25.75 B-7.38%
2021$27.80 B15.71%
2020$24.03 B133.57%
2019$10.28 B23.44%
2018$8.33 B87.28%
2017$4.45 B269.44%
2016$1.20 B

End of Day market cap according to different sources

On Jan 27th, 2022 the market cap of BeiGene was reported to be:

$21.55 Billion
by Yahoo Finance
$21.18 Billion
by CompaniesMarketCap
$20.78 Billion
by Nasdaq
$27.78 Billion
by Reuters
$20.76 Billion
by Iex Cloud

Market capitalization for similar companies or competitors

Name Market cap Market cap difference Country
$1.96 B-91.46%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.03 B-99.85%๐Ÿ‡บ๐Ÿ‡ธ USA